Recent Posts
Recent Comments
- Liz on Pet Hoarders: How many cats are too many? | Dr. Justine Lee
- Kelley on Pet Hoarders: How many cats are too many? | Dr. Justine Lee
- Cora on Focus on Health-Focused Breeding of Dogs
- justinelee on How to euthanize a dog with Tylenol… and why you don’t….
- Susan bergunde on How to euthanize a dog with Tylenol… and why you don’t….
Archives
- February 2022
- August 2021
- December 2020
- November 2020
- August 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- August 2019
- June 2019
- May 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
Recall of Lactated Ringers Solution (LRS) and 5% Dextrose!
Posted by justinelee in Animal Safety, Blog, Recalls
Hospira Issues Voluntary Nationwide Recall Of One Lot Of Lactated Ringers And 5% Dextrose Injection, Usp, 1000 ML, Flexible Containers Due To Mold Contamination
Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary nationwide user-level recall of one lot of Lactated Ringers and 5% Dextrose Injection, USP, 1000 mL, Flexible Container, NDC 0409-7929-09, Lot 35-118-JT, Expiry 1NOV2015 . This action is due to one confirmed customer report where particulate was identified within the solution of the primary container. The particulate was identified as a filamentous-like structured particulate indicative of mold. Analysis of the primary container and overwrap indicated a puncture in the same physical location, causing the primary container to leak.
Intravenous administration of a non-sterile product can result in infections that may be life-threatening, and may result in prolonged hospitalization or organ failure. Hospira has not received reports of any adverse events associated with this issue for this lot to date, and has not identified any quality issues with retention samples for this lot. Hospira has investigated and determined the root cause of the event and has implemented corrective actions to address this issue.
In general, a defect in a container leading to a leak may create a breach in sterility since an open pathway exists for contamination of fluid. If the leak is not detected, and the solution becomes contaminated and it is not identified prior to administration, there is potential that contaminated solution could be administered to the patient.
The product is indicated for parenteral replacement of extracellular losses of fluid and electrolytes, with or without minimal carbohydrate calories, as required by the clinical condition of the patient. The product is packaged in 1000mL flexible containers, 1 container per overwrap, and 12 overwrapped containers in each case. The lot number is located in the upper left hand side of the primary container. This lot was distributed nationwide from December 2013 through February 2014 and was distributed to hospitals, clinics, wholesalers and distributors. This recall is being conducted as a precautionary measure.
Anyone with an existing inventory should stop use and distribution, quarantine the product immediately, and call Stericycle at 1-888-912-8457 between the hours of 8am to 5pm EST, Monday through Friday, to arrange for the return of the product.
For clinical inquiries, please contact Hospira using the information provided below:
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.